<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Data Brief</journal-id><journal-id journal-id-type="iso-abbrev">Data Brief</journal-id><journal-title-group><journal-title>Data in Brief</journal-title></journal-title-group><issn pub-type="epub">2352-3409</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28374000</article-id><article-id pub-id-type="pmc">5367801</article-id><article-id pub-id-type="publisher-id">S2352-3409(17)30098-7</article-id><article-id pub-id-type="doi">10.1016/j.dib.2017.03.022</article-id><article-categories><subj-group subj-group-type="heading"><subject>Data Article</subject></subj-group></article-categories><title-group><article-title>Effects of an 8-month exercise intervention on physical capacity, NT-proBNP, physical activity levels and quality of life data in patients with pulmonary arterial hypertension by NYHA class</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Santos-Lozano</surname><given-names>Alejandro</given-names></name><email>asantos@uemc.es</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Sanz-Ayan</surname><given-names>Paz</given-names></name><xref rid="aff0015" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez-Saiz</surname><given-names>Laura</given-names></name><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Quezada-Loaiza</surname><given-names>Carlos A.</given-names></name><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Fiuza-Luces</surname><given-names>Carmen</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Flox-Camacho</surname><given-names>Angela</given-names></name><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Mungu&#x000ed;a-Izquierdo</surname><given-names>Diego</given-names></name><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Santalla</surname><given-names>Alfredo</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Mor&#x000e1;n</surname><given-names>Mar&#x000ed;a</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Escribano-Sub&#x000ed;as</surname><given-names>Pilar</given-names></name><xref rid="aff0020" ref-type="aff">d</xref><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Lucia</surname><given-names>Alejandro</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0020" ref-type="aff">d</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>Research Institute Hospital 12 de Octubre (&#x005f3;i+12&#x005f3;), Madrid, Spain</aff><aff id="aff0010"><label>b</label>GIDFYS, European University Miguel de Cervantes, Valladolid, Spain</aff><aff id="aff0015"><label>c</label>Department of Rehabilitation, Hospital Universitario 12 de Octubre, Madrid, Spain</aff><aff id="aff0020"><label>d</label>European University, Madrid, Spain</aff><aff id="aff0025"><label>e</label>Pulmonary Hypertension Unit, Hospital Universitario 12 de Octubre, Madrid, Spain</aff><aff id="aff0030"><label>f</label>Department of Sports and Computer Science, Pablo de Olavide University, Sevilla, Spain</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author at: Research Institute Hospital 12 de Octubre (&#x005f3;i+12&#x005f3;), Madrid, Spain.Research Institute Hospital 12 de Octubre (&#x005f3;i+12&#x005f3;)MadridSpain <email>asantos@uemc.es</email></corresp><fn id="fn1"><label>1</label><p id="ntp0005">Contributed equally.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>18</day><month>3</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>6</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>18</day><month>3</month><year>2017</year></pub-date><volume>12</volume><fpage>37</fpage><lpage>41</lpage><history><date date-type="received"><day>15</day><month>12</month><year>2016</year></date><date date-type="rev-recd"><day>17</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>9</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Published by Elsevier Inc.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder/><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="ab0010"><p>This article provides descriptive detailed (pre and post) values of physical capacity variables, NT-proBNP, physical activity levels and quality of life in patients with pulmonary arterial hypertension (PH) (both, intervention and control group) by New York Heart Association (NYHA) class before and after an 8-month exercise intervention. The data are supplemental to our original Randomized Controlled Trial (RCT) entitled &#x0201c;Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial&#x0201d; (L. Gonz&#x000e1;lez-Saiz, C. Fiuza-Luces, F. Sanchis-Gomar, A. Santos-Lozano, C.A. Quezada-Loaiza, A. Flox-Camacho, D. Mungu&#x000ed;a-Izquierdo, I. Ara, A. Santalla, M. Mor&#x000e1;n, P. Sanz-Ayan, P. Escribano-Sub&#x000ed;as, A. Lucia A, 2017) [1].</p></abstract><kwd-group id="keys0005"><title>Keywords</title><kwd>Pulmonary arterial hypertension</kwd><kwd>Physical activity levels</kwd><kwd>Quality of life</kwd><kwd>Physical intervention</kwd></kwd-group></article-meta></front><body><p><bold>Specifications Table</bold><table-wrap id="t0010" position="float"><alt-text id="at0010">Table</alt-text><table frame="hsides" rules="groups"><tbody><tr><td>Subject area</td><td><italic>Medicine</italic></td></tr><tr><td>More specific subject area</td><td><italic>Cardiology</italic></td></tr><tr><td>Type of data</td><td><italic>Table</italic></td></tr><tr><td>How data was acquired</td><td><italic>Functional clinical assessment of the patients and sample blood analysis</italic></td></tr><tr><td>Data format</td><td><italic>Descriptive data: mean</italic>&#x000b1;<italic>SD</italic></td></tr><tr><td>Experimental factors</td><td><italic>Data of the patients with pulmonary arterial hypertension by New York Heart Association class</italic></td></tr><tr><td>Experimental features</td><td><italic>Randomized Controlled Trial</italic></td></tr><tr><td>Data source location</td><td><italic>Madrid, Spain</italic></td></tr><tr><td>Data accessibility</td><td><italic>The data are accessible within the article</italic></td></tr></tbody></table></table-wrap></p><p><bold>Value of the data</bold><list list-type="simple"><list-item id="u0005"><label>&#x02022;</label><p>Data presented here provide the descriptive overview of the PH patients by NYHA class involved in an exercise RCT.</p></list-item><list-item id="u0010"><label>&#x02022;</label><p>We describe the changes in physical capacity-related primary outcomes (peak watts in leg and bench press) and the changes in physical capacity-related secondary outcomes [maximal inspiratory pressure (PImax), 6-minute walking distance (6MWD), and performance time in the 5-repetition sit-to-stand (5-STS) test] of the PAH patients by NYHA class involved in the RCT (control vs. intervention).</p></list-item><list-item id="u0015"><label>&#x02022;</label><p>We describe values of physical activity (PA) levels (min/day in inactivity and moderate-vigorous PA) of PH patients by NYHA class involved in the RCT (control vs. intervention).</p></list-item><list-item id="u0020"><label>&#x02022;</label><p>We show the values of health related quality of life [HRQoL, (mental and physical components of SF-36 questionnaire)] of PH patients by NYHA class involved in the RCT (control vs. intervention).</p></list-item><list-item id="u0025"><label>&#x02022;</label><p>This data could be useful to physicians to make comparisons with other cohort datasets and so to contribute to the knowledge of the PA effect in PH patients by NYHA class.</p></list-item></list></p><sec id="s0005"><label>1</label><title>Data</title><p>Descriptive values of physical capacity-related variables, NT-ProBNP, cardiopulmonary exercise capacity, PA levels and HRQoL of PAH patients involved in the RCT <xref rid="bib2" ref-type="bibr">[2]</xref> (ClinicalTrials.gov ID: <ext-link ext-link-type="uri" xlink:href="ctgov:NCT02288442" id="ir0005">NCT02288442</ext-link>) conducted from January 2015 to June 2016 at the Hospital 12 de Octubre (Madrid, Spain) following the <italic>Consolidated Standards of Reporting Trials</italic> (CONSORT) guidelines <xref rid="bib3" ref-type="bibr">[3]</xref> are shown in <xref rid="t0005" ref-type="table">Table 1</xref>.</p></sec><sec id="s0010"><label>2</label><title>Experimental design, materials and methods</title><p>20 PH patients were involved in the intervention group of the RCT and 20 PH patients in the control group. The RCT intervention lasted 8 weeks and included 3 main components: aerobic and muscle resistance, and specific inspiratory muscle training. All sessions were supervised by experienced fitness instructors. Data outcome (by order of aquisition) were: i) blood sampling for NT-proBNP determination, PImax, 6MWD, muscle power, 5-STS, and distribution of HRQoL questionnaire (1st day); ii) cardiopulmonary exercise testing (after 2&#x02013;3 days to allow recovery from power testing); and iii) seven days of accelerometry recording for objective PA determination. Please see Gonzalez-Saiz et al. (2017) <xref rid="bib1" ref-type="bibr">[1]</xref> for detailed information.</p></sec></body><back><ref-list id="bibliog0005"><title>References</title><ref id="bib1"><label>1</label><mixed-citation publication-type="other" id="othref0005">L. Gonz&#x000e1;lez-Saiz, C. Fiuza-Luces, F. Sanchis-Gomar, A. Santos-Lozano, C. Quezada-Loaiza, A. Flox-Camacho, D. Mungu&#x000ed;a-Izquierdo, I. Ara, A. Santalla, M. Mor&#x000e1;n, P. Sanz-Ayan, P. Escribano-Sub&#x000ed;as, A. Lucia Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial. Int. J. Cardiol., 231, 2017, 277&#x02013;283.</mixed-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sbref1"><person-group person-group-type="author"><name><surname>Sanchis-Gomar</surname><given-names>F.</given-names></name><name><surname>Gonzalez-Saiz</surname><given-names>L.</given-names></name><name><surname>Sanz-Ayan</surname><given-names>P.</given-names></name><name><surname>Fiuza-Luces</surname><given-names>C.</given-names></name><name><surname>Quezada-Loaiza</surname><given-names>C.A.</given-names></name><name><surname>Flox-Camacho</surname><given-names>A.</given-names></name></person-group><article-title>Rationale and design of a randomized controlled trial evaluating whole muscle exercise training effects in outpatients with pulmonary arterial hypertension (WHOLEi+12)</article-title><source>Cardiovasc. Drugs. Ther.</source><volume>29</volume><issue>6</issue><year>2015</year><fpage>543</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">26521182</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sbref2"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D.</given-names></name><name><surname>Hopewell</surname><given-names>S.</given-names></name><name><surname>Schulz</surname><given-names>K.F.</given-names></name><name><surname>Montori</surname><given-names>V.</given-names></name><name><surname>G&#x000f8;tzsche</surname><given-names>P.C.</given-names></name><name><surname>Devereaux</surname><given-names>P.J.</given-names></name><name><surname>Elbourne</surname><given-names>D.</given-names></name><name><surname>Egger</surname><given-names>M.</given-names></name><name><surname>Altman</surname><given-names>D.G.</given-names></name></person-group><article-title>CONSORT. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</article-title><source>Int. J. Cardiol.</source><volume>10</volume><issue>1</issue><year>2012</year><fpage>28</fpage><lpage>55</lpage></element-citation></ref></ref-list><sec id="s0020" sec-type="supplementary-material"><label>Transparency document</label><title>Supplementary material</title><p><supplementary-material content-type="local-data" id="ec0005"><caption><p>Supplementary material</p></caption><media xlink:href="mmc1.docx"/></supplementary-material>.</p></sec><ack id="ack0005"><title>Acknowledgments</title><p>We acknowledge POWERbreathe International Ltd., through BIOCORP EUROPA S.L./ POWERbreathe Spain, for the kind donation of equipment for inspiratory muscle training. This study was funded by a grant from <funding-source id="gs1">C&#x000e1;tedra Real Madrid-Universidad Europea</funding-source> (Grant number P2015/05RM) and L.G.S was supported by a research training scholarship from GSK to conduct the study. The research of AL is funded by the <funding-source id="gs3">Fondo de Investigaciones Sanitarias and Fondos FEDER</funding-source> (grant # PI12/00914).</p></ack><fn-group><fn id="s0015" fn-type="supplementary-material"><label>Transparency document</label><p>Transparency data associated with this article can be found in the online version at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.dib.2017.03.022" id="ir0010">http://dx.doi.org/10.1016/j.dib.2017.03.022</ext-link>.</p></fn></fn-group></back><floats-group><table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Results of the primary and secondary end points by group and NYHA class.</p></caption><alt-text id="at0005">Table 1</alt-text><table frame="hsides" rules="groups"><tbody><tr><td/><td/><td colspan="3"><bold>NYHA Class I</bold><hr/></td><td colspan="3"><bold>NYHA Class I-II</bold><hr/></td><td colspan="3"><bold>NYHA Class II</bold><hr/></td><td colspan="2"><bold>NYHA Class II-III</bold><hr/></td><td/><td colspan="3"><bold>NYHA Class III</bold><hr/></td></tr><tr><td><bold>End points</bold></td><td><bold>Group</bold></td><td><bold><italic>N</italic> with initial data</bold></td><td><bold>Baseline</bold></td><td><bold>Post</bold></td><td><bold><italic>N</italic> with initial data</bold></td><td><bold>Baseline</bold></td><td><bold>Post</bold></td><td><bold><italic>N</italic> with initial data</bold></td><td><bold>Baseline</bold></td><td><bold>Post-</bold></td><td><bold><italic>N</italic> with initial data</bold></td><td><bold>Baseline</bold></td><td><bold>Post</bold></td><td><bold><italic>N</italic> with initial data</bold></td><td><bold>Baseline</bold></td><td><bold>Post</bold></td></tr><tr><td colspan="17"><hr/></td></tr><tr><td><bold>Primary</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Leg press</td><td>Control</td><td>6</td><td>551&#x000b1;285</td><td>583&#x000b1;200</td><td>2</td><td>413&#x000b1;178</td><td>347</td><td>9</td><td>308&#x000b1;138</td><td>323&#x000b1;130</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>206&#x000b1;136</td><td>138</td></tr><tr><td>(peak watts)</td><td>Exercise</td><td>3</td><td>372&#x000b1;96</td><td>471&#x000b1;130</td><td>2</td><td>451&#x000b1;437</td><td>666&#x000b1;584</td><td>11</td><td>307&#x000b1;234</td><td>507&#x000b1;297</td><td>4</td><td>310&#x000b1;221</td><td>470&#x000b1;241</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>Bench press</td><td>Control</td><td>5</td><td>297&#x000b1;130</td><td>325&#x000b1;135</td><td>2</td><td>101&#x000b1;28</td><td>93</td><td>10</td><td>119&#x000b1;79</td><td>121&#x000b1;59</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>74&#x000b1;34</td><td>65</td></tr><tr><td>(peak watts)</td><td>Exercise</td><td>3</td><td>151&#x000b1;113</td><td>187&#x000b1;99</td><td>2</td><td>175&#x000b1;174</td><td>230&#x000b1;212</td><td>11</td><td>113&#x000b1;76</td><td>173&#x000b1;118</td><td>4</td><td>109&#x000b1;83</td><td>162&#x000b1;72</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td><bold>Secondary</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td><italic>Blood variables</italic></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>NT-proBNP</td><td>Control</td><td>4</td><td>63&#x000b1;39</td><td>35&#x000b1;112</td><td>2</td><td>141&#x000b1;55</td><td>112</td><td>8</td><td>270&#x000b1;277</td><td>427&#x000b1;560</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>344&#x000b1;337</td><td>598</td></tr><tr><td>(pg/mL)</td><td>Exercise</td><td>3</td><td>560&#x000b1;327</td><td>710&#x000b1;558</td><td>2</td><td>256&#x000b1;193</td><td>193&#x000b1;117</td><td>11</td><td>235&#x000b1;210</td><td>210&#x000b1;177</td><td>4</td><td>264 &#x000b1;205</td><td>263&#x000b1;165</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td><bold>CET</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>VO<sub>2peak</sub></td><td>Control</td><td>6</td><td>27.3&#x000b1;5.4</td><td>27.9&#x000b1;5.9</td><td>2</td><td>18.2&#x000b1;0.3</td><td>19</td><td>9</td><td>16.5&#x000b1;2.8</td><td>15.5&#x000b1;3.12</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>13&#x000b1;1.4</td><td>14</td></tr><tr><td>(mL/kg/min)</td><td>Exercise</td><td>3</td><td>16.7&#x000b1;0.56</td><td>19&#x000b1;1</td><td>2</td><td>17.3&#x000b1;3.7</td><td>21.3&#x000b1;1.7</td><td>11</td><td>15.2&#x000b1;3.4</td><td>17.3&#x000b1;2.9</td><td>4</td><td>15.2&#x000b1;4.6</td><td>17.4&#x000b1;4.2</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td rowspan="2">P<sub>ET</sub>CO<sub>2</sub>@AT (mmHg)</td><td>Control</td><td>6</td><td>28&#x000b1;3</td><td>30&#x000b1;2</td><td>2</td><td>26&#x000b1;1</td><td>27</td><td>8</td><td>32&#x000b1;6</td><td>30&#x000b1;7</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>21&#x000b1;5</td><td>22</td></tr><tr><td>Exercise</td><td>3</td><td>24&#x000b1;6</td><td>24&#x000b1;6</td><td>2</td><td>25&#x000b1;2</td><td>23&#x000b1;3</td><td>11</td><td>28&#x000b1;7</td><td>27&#x000b1;7</td><td>4</td><td>27&#x000b1;4</td><td>26&#x000b1;7</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>P<sub>ET</sub>O<sub>2</sub>@AT</td><td>Control</td><td>6</td><td>113&#x000b1;4</td><td>111&#x000b1;2</td><td>2</td><td>115&#x000b1;2</td><td>113</td><td>8</td><td>110&#x000b1;5</td><td>111&#x000b1;5</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>119&#x000b1;4</td><td>118</td></tr><tr><td>(mmHg)</td><td>Exercise</td><td>3</td><td>116&#x000b1;6</td><td>116&#x000b1;3</td><td>2</td><td>115&#x000b1;5</td><td>118&#x000b1;3</td><td>11</td><td>113&#x000b1;6</td><td>115&#x000b1;6</td><td>4</td><td>114&#x000b1;6</td><td>113&#x000b1;8</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td rowspan="2">V<sub>E</sub>/VCO<sub>2</sub>@AT</td><td>Control</td><td>6</td><td>42&#x000b1;7</td><td>39&#x000b1;4</td><td>2</td><td>42&#x000b1;5</td><td>37&#x000b1;4</td><td>8</td><td>38&#x000b1;7</td><td>39&#x000b1;9</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>52&#x000b1;16</td><td rowspan="2">52</td></tr><tr><td>Exercise</td><td>3</td><td>45&#x000b1;11</td><td>45&#x000b1;12</td><td>2</td><td>43&#x000b1;2</td><td>47&#x000b1;5</td><td>11</td><td>41&#x000b1;11</td><td>44&#x000b1;13</td><td>4</td><td>43&#x000b1;7</td><td>43&#x000b1;10</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td rowspan="2">V<sub>E</sub>/VO<sub>2</sub>@AT</td><td>Control</td><td>6</td><td>45&#x000b1;9</td><td>43&#x000b1;4</td><td>2</td><td>45&#x000b1;2</td><td>43</td><td>8</td><td>40&#x000b1;6</td><td>43&#x000b1;10</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td rowspan="2">58&#x000b1;19</td><td rowspan="2">62</td></tr><tr><td>Exercise</td><td>3</td><td>52&#x000b1;16</td><td>54&#x000b1;16</td><td>2</td><td>46&#x000b1;5</td><td>53&#x000b1;7</td><td>11</td><td>46&#x000b1;12</td><td>49&#x000b1;13</td><td>4</td><td>48&#x000b1;11</td><td>48&#x000b1;17</td><td>&#x02013;</td></tr><tr><td><bold>Other physical capacity variables</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>PI<sub>max</sub></td><td>Control</td><td>6</td><td>97&#x000b1;32</td><td>100&#x000b1;34</td><td>2</td><td>66&#x000b1;10</td><td>60</td><td>9</td><td>68&#x000b1;24</td><td>69&#x000b1;26</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>38&#x000b1;27</td><td>83</td></tr><tr><td>(cmH<sub>2</sub>O)</td><td>Exercise</td><td>3</td><td>62&#x000b1;33</td><td>102&#x000b1;41</td><td>2</td><td>74&#x000b1;66</td><td>105&#x000b1;90</td><td>11</td><td>81&#x000b1;39</td><td>110&#x000b1;25</td><td>4</td><td>70&#x000b1;26</td><td>117&#x000b1;16</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>6MWD</td><td>Control</td><td>6</td><td>639&#x000b1;97</td><td>620&#x000b1;154</td><td>2</td><td>579&#x000b1;43</td><td>549</td><td>10</td><td>497&#x000b1;75</td><td>491&#x000b1;45</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>480&#x000b1;17</td><td>492</td></tr><tr><td>(meters)</td><td>Exercise</td><td>3</td><td>549&#x000b1;36</td><td>572&#x000b1;15</td><td>2</td><td>504&#x000b1;77</td><td>549&#x000b1;43</td><td>11</td><td>495&#x000b1;76</td><td>512&#x000b1;74</td><td>4</td><td>475&#x000b1;73</td><td>517&#x000b1;90</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td rowspan="2">5-STS (performance time, seconds**)</td><td>Control</td><td>6</td><td>6.2&#x000b1;1.2</td><td>5.9&#x000b1;1</td><td>2</td><td>5.1&#x000b1;1</td><td>5.2&#x000b1;1</td><td>10</td><td>7.8&#x000b1;1.5</td><td>7.6&#x000b1;1.2</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>6.8</td><td>8.1</td></tr><tr><td>Exercise</td><td>3</td><td>6.5&#x000b1;2</td><td>5.8&#x000b1;2</td><td>2</td><td>6.5&#x000b1;2</td><td>5.5&#x000b1;1</td><td>11</td><td>8&#x000b1;1.5</td><td>6.1&#x000b1;1.3</td><td>3</td><td>7.3&#x000b1;1</td><td>6.1&#x000b1;1</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td><td>&#x02028;&#x02028;</td></tr><tr><td><bold>PA levels</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td rowspan="2">Inactivity time (min/day)</td><td>Control</td><td>3</td><td>531&#x000b1;154</td><td>573&#x000b1;100</td><td>1</td><td>605</td><td>674</td><td>7</td><td>549&#x000b1;109</td><td>581&#x000b1;76</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>604&#x000b1;26</td><td>668&#x000b1;61</td></tr><tr><td>Exercise</td><td>3</td><td>562&#x000b1;40</td><td>583&#x000b1;53</td><td>2</td><td>621&#x000b1;136</td><td>409&#x000b1;12</td><td>6</td><td>554&#x000b1;93</td><td>536&#x000b1;85</td><td>4</td><td>573&#x000b1;148</td><td>630&#x000b1;101</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>MVPA</td><td>Control</td><td>3</td><td>42&#x000b1;29</td><td>26&#x000b1;20</td><td>1</td><td>42</td><td>49</td><td>6</td><td>45&#x000b1;26</td><td>32&#x000b1;21</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>20&#x000b1;22</td><td>16&#x000b1;10</td></tr><tr><td>(min/day)</td><td>Exercise</td><td>3</td><td>58&#x000b1;12</td><td>13&#x000b1;11</td><td>2</td><td>42&#x000b1;22</td><td>49&#x000b1;5</td><td>6</td><td>28&#x000b1;19</td><td>42&#x000b1;18</td><td>4</td><td>44&#x000b1;28</td><td>34&#x000b1;7</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td><bold>HRQoL (SF-36)</bold></td><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Mental</td><td>Control</td><td>3</td><td>56&#x000b1;6</td><td>53&#x000b1;7</td><td>1</td><td>58</td><td>62</td><td>7</td><td>47&#x000b1;12</td><td>53&#x000b1;7</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>49&#x000b1;12</td><td>38</td></tr><tr><td>component</td><td>Exercise</td><td>3</td><td>49&#x000b1;12</td><td>38</td><td>2</td><td>54&#x000b1;4</td><td>59&#x000b1;5</td><td>10</td><td>45&#x000b1;10</td><td>53&#x000b1;10</td><td>4</td><td>56&#x000b1;6</td><td>52&#x000b1;9</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td rowspan="2">Physical component</td><td>Control</td><td>3</td><td>44&#x000b1;4</td><td>49&#x000b1;6</td><td>1</td><td>50</td><td>46</td><td>8</td><td>39&#x000b1;7</td><td>43&#x000b1;7</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td>2</td><td>35&#x000b1;1</td><td>41</td></tr><tr><td>Exercise</td><td>3</td><td>39&#x000b1;9</td><td>42&#x000b1;8</td><td>2</td><td>45&#x000b1;0.2</td><td>50&#x000b1;1</td><td>10</td><td>37&#x000b1;7</td><td>42&#x000b1;6</td><td>4</td><td>30&#x000b1;6</td><td>33&#x000b1;9</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td></tr></tbody></table><table-wrap-foot><fn><p>Data are mean&#x000b1;SD. Abbreviations: 6MWD, 6-minute walking distance; 5-STS, 5-repetition sit-to-stand; CET, cardiopulmonary exercise testing: HRQoL, health-related quality of life; MVPA, moderate-vigorous physical activity; NT-proBNP (pg/mL), N-terminal pro-B-type-natriuretic peptide; P<sub>ET</sub>CO<sub>2</sub>@AT, end-tidal pressure of carbon dioxide at the anaerobic threshold; P<sub>ET</sub>O<sub>2</sub>@AT, end-tidal pressure of oxygen at the anaerobic threshold; PI<sub>max</sub>, maximal inspiratory pressure; SF-36, Short Form-36 Item Health Survey; V<sub>E</sub>/VCO<sub>2</sub>@AT, ventilatory equivalent for carbon dioxide at the anaerobic threshold; V<sub>E</sub>/VO<sub>2</sub>@AT, ventilatory equivalent for oxygen at the anaerobic threshold; VO<sub>2peak</sub>, peak oxygen uptake.</p></fn></table-wrap-foot></table-wrap></floats-group></article>